Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs

Publication date: Available online 15 June 2017
Source:Advanced Drug Delivery Reviews
Author(s): Wei Huang, Liqing Chen, Lin Kang, Mingji Jin, Ping Sun, Xin Xin, Zhonggao Gao, You Han Bae
Anticancer therapy has always been a vital challenge for the development of nanomedicine. Repeated single therapeutic agent may lead to undesirable and severe side effects, unbearable toxicity and multidrug resistance due to complex nature of tumor. Nanomedicine-based combination anticancer therapy can synergistically improve antitumor outcomes through multiple-target therapy, decreasing the dose of each therapeutic agent and reducing side effects. There are versatile combinational anticancer strategies such as chemotherapeutic combination, nucleic acid-based co-delivery, intrinsic sensitive and extrinsic stimulus combinational patterns. Based on these combination strategies, various nanocarriers and drug delivery systems were engineered to carry out the efficient co-delivery of combined therapeutic agents for combination anticancer therapy. This review focused on illustrating nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs for synergistically improving anticancer efficacy.

Graphical abstract

http://ift.tt/2rntZo5